Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2-breast cancer

被引：2
作者：
Wander, S. A.
Spring, L. M.
Stein, C. R.
Yuen, M.
Zangardi, M.
O'Shaughnessy, J.
Bardia, A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-18-39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-18-39
引用
收藏
页数：2
相关论文
共 50 条
[31]   Hiding in plain sight: A heterogeneous response in a patient with metastatic HR+/HER2-breast cancer [J].
Priedigkeit, Nolan ;
Brock, Jane ;
Cunningham, Olivia ;
Skeffington, Molly ;
Hughes, Melissa ;
Lin, Nancy ;
Lester, Susan ;
Parsons, Heather .
CANCER RESEARCH, 2024, 84 (09)
[32]   Abemaciclib with or without fulvestrant for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with disease progression following prior treatment with palbociclib. [J].
Tamragouri, Keerthi ;
Cobleigh, Melody A. ;
Rao, Ruta D. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[33]   Comparison of healthcare resource utilization and costs in women with HR+/HER2-metastatic breast cancer treated with ribociclib vs palbociclib or abemaciclib [J].
Balu, Sanjeev ;
Burne, Rebecca ;
Guerin, Annie ;
Bungay, Rebecca ;
Paul, Mary Lisha ;
Sin, Roxana .
CANCER RESEARCH, 2021, 81 (04)
[34]   Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2-metastatic breast cancer: A single center real-world study in China [J].
Jiang, Hanfang ;
Zhong, Jianxin ;
Wang, Jing ;
Song, Guohong ;
Di, Lijun ;
Shao, Bin ;
Zhang, Ruyan ;
Liu, Yaxin ;
Zhu, Anjie ;
Wang, Nan ;
Li, Huiping .
CANCER MEDICINE, 2024, 13 (10)
[35]   Impact of early dose reduction of palbociclib on clinical outcomes in patients with hormone-receptor positive metastatic breast cancer [J].
Moftakhar, Bahar ;
Lekkala, Manidhar Reddy ;
Strawderman, Myla ;
Smith, Tae C. ;
Meacham, Philip ;
Fitzgerald, Bryan ;
Dhakal, Ajay .
CANCER RESEARCH, 2020, 80 (04)
[36]   Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment [J].
Dhakal, Ajay ;
Matthews, Christina M. ;
Levine, Ellis Glenn ;
Salerno, Kilian Elizabeth ;
Zhang, Fan ;
Takabe, Kazuaki ;
Early, Amy P. ;
Edge, Stephen B. ;
O'Connor, Tracy ;
Khoury, Thaer ;
Young, Jessica S. ;
Opyrcha, Mateusz .
CLINICAL BREAST CANCER, 2018, 18 (06) :E1401-E1405
[37]   Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2-breast cancer: Incidence and impact on clinical outcomes [J].
Medford, Arielle ;
Niemierko, Andrzej ;
Moy, Beverly ;
Spring, Laura ;
Malvarosa, Giuliana ;
Younger, Jerry ;
Lanman, Richard B. ;
Nagy, Rebecca J. ;
Corcoran, Ryan Bruce ;
Isakoff, Steven J. ;
Ellisen, Leif W. ;
Juric, Dejan ;
Bardia, Aditya .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[38]   The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer [J].
Tajiri, Wakako ;
Nakamura, Yoshiaki ;
Kawasaki, Junji ;
Koi, Yumiko ;
Akiyoshi, Sayuri ;
Koga, Chinami ;
Tokunaga, Eriko .
CANCER RESEARCH, 2024, 84 (09)
[39]   Incidence and management of diarrhoea associated with abemaciclib and endocrine therapy for hormone-receptor positive, HER2-negative metastatic breast cancer: the UK patients’ experiences [J].
Helena Harder ;
Rachel Starkings ;
Lesley Fallowfield ;
Shirley May ;
Valerie Shilling .
Supportive Care in Cancer, 2025, 33 (5)
[40]   Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2-metastatic breast cancer [J].
Fitzgerald, D. M. ;
Henderson, L. E. ;
Isakoff, S. J. ;
Moy, B. ;
Oh, K. ;
Shih, H. A. ;
Dias-Santagata, D. ;
Borger, D. R. ;
Iafrate, A. J. ;
Brastianos, P. K. ;
Bardia, A. ;
Juric, D. .
CANCER RESEARCH, 2017, 77
12345